Impact of Prostate Needle Biopsy on Erectile Function

Temel Bulgular & Veri:All patients were evaluated with the 5-item version of the International Index of Erectile Function (IIEF-5) before TRUS-Bx and at one, three and six months after TRUS-Bx.

💡

Sonuç & Katkı:It seemed to be a trend toward increasing ED at 1 month and longer follow-up showed that these changes resolved back to baseline.

🔬Tür:Araştırma Makalesi

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Özet

Aim: To evaluate the impact of transrectal ultrasonography-guided prostate needle biopsy (TRUS-Bx) on erectile function. Methods: Patients who underwent TRUS-Bx were prospectively examined. The indications for prostate biopsy were elevated prostatespecific antigen (PSA) level and/or abnormal digital rectal examination. All patients were evaluated with the 5-item version of the International Index of Erectile Function (IIEF-5) before TRUS-Bx and at one, three and six months after TRUS-Bx. Severity of erectile dysfunction (ED) was classified into five categories according to IIEF-5 scores. Results: Eighty patients were included in the study. The mean age of the patients was 64.7 years and the mean serum PSA level was 10.2 ng/mL. The mean IIEF-5 score was 16.5 prior to TRUS-Bx. Before TRUSBx, ED was reported in 61 patients and mild, mild to moderate, and moderate ED in 23 (28.8%), 21 (26.2%), and 17 (21.2%) patients, respectively. Six months after TRUS-Bx, ED was reported as mild, mild to moderate, moderate and severe in 23 (28.8%), 21 (26.3%), 16 (20%) and one (1.3%) patients, respectively. The differences between before and after prostate biopsy were statistically insignificant (p>0.05). Conclusion: TRUS-Bx does not have a permanent effect on erectile function. It seemed to be a trend toward increasing ED at 1 month and longer follow-up showed that these changes resolved back to baseline.

Abstract

Amaç: Transrektal ultrasonografi eşliğinde prostat iğne biyopsisinin (TRUS-Bx) erektil fonksiyon üzerine etkisini değerlendirmektir. Yöntemler: TRUS-Bx yapılan hastalar prospektif olarak incelendi. Prostat biyopsisi endikasyonları; yüksek veya artan prostat spesifik antijen (PSA) ve/veya anormal parmakla rektal muayene idi. Tüm hastalar TRUS-Bx öncesinde ve TRUS-Bx sonrası birinci, üçüncü ve altıncı aylarda Uluslararası Erektil Fonksiyon indeksinin (IIEF-5) 5 maddelik versiyonu ile değerlendirildi. Erektil disfonksiyon (ED) şiddeti, IIEF-5 skorlarına göre beş kategoriye ayrıldı. Bulgular: Seksen hasta çalışmaya dahil edildi. Hastaların ortalama yaşı 64,7 ve ortalama serum PSA düzeyi 10,2 ng/mL idi. Ortalama IIEF-5 skoru TRUS-Bx öncesi 16,5 idi. TRUS-Bx öncesi 61 hastada ED vardı ve hafif, hafif-orta ve orta derece ED’li hasta sayısı sırasıyla 23 (%28,8), 21 (%26,2) ve 17 (%21,2) idi. TRUS-Bx’den altı ay sonra ED, sırasıyla 23 (%28,8), 21 (%26,3), 16 (%20) ve bir (%1,3) hastada hafif, hafiforta, orta ve şiddetli olarak rapor edildi. Bu farklar istatistiksel olarak anlamsızdı (p>0,05). Sonuç: TRUS-Bx’nin erektil işlev üzerinde kalıcı bir etkisi yoktur. Birinci ayda ED’nin artması yönünde bir eğilim olsa da, uzun dönem takipte bu değişiklikler işlem öncesi değerlere geri dönmektedir.

🔖

Bu Makaleye Atıf Yap

YANARAL, F., ÖZGÖR, F., SAVUN, M., AYRANCI, A., ÇAĞLAR, U., ÇUBUK, A., SARILAR, Ö. (2019). Impact of Prostate Needle Biopsy on Erectile Function. Haseki Tıp Bülteni, Cilt: 57 - Sayı: 1, 47–50. https://ajindex.com/articles/164771

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: E359-86. Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-92.
Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEERMedicare. J Urol 2011;186:1830-4.
Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT Study. BMJ 2012;344:d7894. Zisman A, Leibovici D, Kleinmann J, Cooper A, Siegel Y, Lindner A. The impact of prostate biopsy on patient wellbeing: a prospective study of voiding impairment. J Urol 2001;166:2242-6.
Bozlu M, Ulusoy E, Doruk E, et al. Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsydecrease this morbidity? Urology 2003;62:1050-3.
Chrisofos M, Papatsoris AG, Dellis A, Varkarakis IM, Skolarikos A, Deliveliotis C. Can prostate biopsies affect erectile function? Andrologia 2006;38:79-83.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
Glaser AP, Novakovic K, Helfand BT. The impact of prostate biopsy on urinary symptoms, erectile function, and anxiety. Curr Urol Rep 2012;13:447-54.
Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified International Index of Erectile Function (IIEF5) as a diagnostic tool to study the prevalence of erectile dysfunction. Int J Impot Res 2002;14:245-50.
Turunç T, Deveci S, Güvel S, Peşkircioğlu, L. The assessment of Turkish validation with 5 question version of International Index of Erectile Function (IIEF-5). Türk Üroloji Dergisi 2007;33:45-9.
Helfand BT, Glaser AP, Rimar K, et al. Prostate cancer diagnosis is associated with an increased risk of erectile dysfunctionafter prostate biopsy. BJU Int 2013;111:38-43.
Zisman A, Leibovici D, Kleinmann J, Siegel YI, Lindner A. The impact of prostate biopsy on patient well-being: a prospective study of pain, anxiety and erectile dysfunction. J Urol 2001;165:445-54.
Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664-9.
Akbal C, Türker P, Tav